Because of the relative ineffectiveness of systemic chemotherapy, the majority of therapeutic agents are delivered to many patients to actually benefit only a few. This defensive treatment strategy is also driven by the paucity of effective surrogate markers predicting response. Even molecularly targeted therapies may have relatively poor response rates in the presence of the known target. In order to change the current practice, effective predictors of response are needed. We have recently developed a family of molecular classifiers capable of predicting histological origin of 21 different tumor types with a high degree of accuracy. We hypothesize that, using a genome-wide gene expression profiling strategy similarly effective classifiers can be built to recognize chemosensitive tumors. This proposal will fund a Phase II trial of standard chemotherapy for metastatic colorectal cancer that will seek to identify molecular fingerprints common to chemosensitive tumors. Because there are now two equally effective regimens (FOLFOX vs FOLFIRI) available for first line therapy of metastatic colon cancer, we will seek to derive an expressed genetic profile that will predict response to a more practical modification of each of these regimens (XELOX vs CAMCAPE) with a high degree of accuracy. Furthermore, we will determine if the subset of patients responding to CAMCAPE is the same as the subset responding to XELOX. Finally, we will validate the expression and characterize the function of informative genes useful in tumor classification. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA101355-02
Application #
6800815
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Xie, Heng
Project Start
2003-09-12
Project End
2007-08-31
Budget Start
2004-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2004
Total Cost
$362,675
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314
Ahmed, Kamran A; Caudell, Jimmy J; El-Haddad, Ghassan et al. (2016) Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1399-1404
Ahmed, Kamran A; Chinnaiyan, Prakash; Fulp, William J et al. (2015) The radiosensitivity index predicts for overall survival in glioblastoma. Oncotarget 6:34414-22
Torres-Roca, Javier F; Fulp, William J; Caudell, Jimmy J et al. (2015) Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. Int J Radiat Oncol Biol Phys 93:631-8
Strom, Tobin; Hoffe, Sarah E; Fulp, William et al. (2015) Radiosensitivity index predicts for survival with adjuvant radiation in resectable pancreatic cancer. Radiother Oncol 117:159-64
Ahmed, Kamran A; Fulp, William J; Berglund, Anders E et al. (2015) Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. Int J Radiat Oncol Biol Phys 92:837-42
Eschrich, Steven A; Fulp, William J; Pawitan, Yudi et al. (2012) Validation of a radiosensitivity molecular signature in breast cancer. Clin Cancer Res 18:5134-43
Eschrich, Steven A; Pramana, Jimmy; Zhang, Hongling et al. (2009) A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 75:489-96
Bloom, Gregory C; Eschrich, Steven; Zhou, Jeff X et al. (2007) Elucidation of a protein signature discriminating six common types of adenocarcinoma. Int J Cancer 120:769-75
Alvarado, Michael D; Jensen, Eric H; Yeatman, Timothy J (2006) The potential role of gene expression in the management of primary and metastatic colorectal cancer. Cancer Control 13:27-31

Showing the most recent 10 out of 12 publications